Printer Friendly

MEDraysintell Will Display Its Series of Market Reports at EANM Congress in Vienna.

Louvain-la-Neuve, Belgium, October 11, 2017 --(PR.com)-- MEDraysintell will display its series of market reports and directories with over 2,100 pages of unrivaled intelligence covering Nuclear Medicine, Cyclotrons, Brachytherapy and Proton Therapy, during the EANM - European Association of Nuclear Medicine - congress (Vienna, Austria, October 21-25, 2017). http://eanm17.eanm.org/. MEDraysintell is gratefully hosted by the company ANMI and visitors are welcome at booth #318.

With the recent official approval of 177Lu-Lutathera by EMA for the European market, triggering further the interest of big pharmas for Advanced Accelerator Applications, and the 177Lu-PSMA-617 rights licensed by Endocyte from ABX, it is now obvious that nuclear medicine and in particular its therapeutic potential becomes of high priority for new investors. Radiotherapeutics will soon become part of their portfolio at the same level if not more efficient than chemotherapies.

In the past few months several other key events have confirmed the trend of an increasing interest for the nuclear medicine market, such as Jubilant Pharma acquiring Triad Isotopes, Sofie Biosciences purchasing Zevacor Pharma, Theragnostics Ltd. partnering with ROTOP Pharmaka, ARTMS Products and GE Healthcare teaming up on cyclotron targets, Telix Pharma and CellSight concluding license agreement or Konica Minolta taking over InviCRO.

Radiotherapeutics are multiplying the prospects for profitability and thus attract several major investors and in particular conventional pharmaceutical companies which have started showing a stronger interest over the last few years, a trend that will definitely increase in the near future. Additionally, by linking radiodiagnostics to radiotherapeutics, this technology demonstrated clearly the concept of Theranostics. Imaging allows selecting the positive responders and the follow-up therapy with an analogue therapeutic molecule increases dramatically the efficacy of treatment in this well-defined sub-group of patients.

A growing number of companies, often start-ups, are developing radiopharmaceuticals on this basis and will soon need to link with larger partners and/or investors.

MEDraysintell reports and directories are becoming the sole trusted sources of intelligence in the radiation healthcare industry. Reports can be customized to specific areas or modalities. Sample pages and complete table of contents are available upon request. MEDraysintell also welcomes your requests for specific intelligence needs in these areas.

They look forward to seeing you in Vienna!

Contact Information:

MEDraysintell

Paul-Emmanuel Goethals

+32 491 080 968

Contact via Email

www.medraysintell.com

Richard Zimmermann

+33 6 82 80 06 00

Read the full story here: http://www.pr.com/press-release/732373

COPYRIGHT 2017 PR.com
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR.com (Press Releases)
Geographic Code:4EUAU
Date:Oct 11, 2017
Words:398
Previous Article:Kaltra Extends Its Portfolio with Evaporative Condensers and Dry Coolers.
Next Article:Georgia Nurses Association's New Brand Delivers Increased Value to Members.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters